Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 18/20 | 0.58 |
| ▸ | XIAP | P98170 | 16/20 | 0.58 |
| ▸ | BIRC3 | Q13489 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731929 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL12568679 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL2731495 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL2731493 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL2731933 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL18494147 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL19309145 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL20231032 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL20334443 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL10127375 | 0.99 | BIRC2 (0.59) | BIRC2XIAPBIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296581-A1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2022-09-22 | — | — | US | claimed |
| US-11382905-B2 | Immunomodulation by IAP inhibitors | NOVARTIS AG (CH) | 2022-07-12 | — | — | US | claimed |
| US-20200345714-A1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2020-11-05 | — | — | US | claimed |
| US-10786491-B2 | Immunomodulation by IAP inhibitors | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | claimed |
| US-20170368047-A1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2017-12-28 | — | — | US | claimed |
| CN-101340947-B | Combination of an iap-inhibitor and a taxane7 | NOVARTIS AG | 2012-09-05 | — | — | CN | claimed |
| EP-1735307-B1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | claimed |
| JP-2011524339-A | — | — | 2011-09-01 | — | — | JP | claimed |
| CN-102099035-A | Immunomodulation by IAP inhibitors | NOVARTIS AG | 2011-06-15 | — | — | CN | claimed |
| US-20110135691-A1 | IMMUNOMODULATION BY IAP INHIBITORS | NOVARTIS AG | 2011-06-09 | — | — | US | claimed |
| EP-2296650-A1 | IMMUNOMODULATION BY IAP INHIBITORS | Novartis AG (CH) | 2011-03-23 | — | — | EP | claimed |
| WO-2009140447-A1 | IMMUNOMODULATION BY IAP INHIBITORS | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | claimed |
| EP-2065368-A1 | Inhibitors of IAP | Novartis Ag (CH) | 2009-06-03 | — | — | EP | claimed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | claimed |
| WO-2008109057-A1 | ORGANIC COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2008-09-12 | — | — | WO | claimed |
| EP-1735307-A1 | INHIBITORS OF IAP | Novartis AG (CH) | 2006-12-27 | — | — | EP | claimed |
| US-20050234042-A1 | Organic compounds | PALERMO MARK G | 2005-10-20 | — | — | US | claimed |
| WO-2005097791-A1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | claimed |
| US-20220296581-A1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2022-09-22 | — | — | US | disclosed |
| US-20050234042-A1 | Organic compounds | PALERMO MARK G | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | BIRC2 2/4885XIAP 1/4885BIRC3 5/4885 |
| US-20220296581-A1 | Immunomodulation by IAP Inhibitors | BIRC2, BIRC3, BIRC5 | BIRC2 1/4885XIAP 6/4885BIRC3 2/4885 |
| US-10786491-B2 | Immunomodulation by IAP inhibitors | BIRC2, BIRC3, BIRC5 | BIRC2 1/4885XIAP 6/4885BIRC3 2/4885 |
| US-20170368047-A1 | Immunomodulation by IAP Inhibitors | BIRC2, BIRC3, BIRC5 | BIRC2 1/4885XIAP 6/4885BIRC3 2/4885 |
| US-11382905-B2 | Immunomodulation by IAP inhibitors | BIRC2, BIRC3, BIRC5 | BIRC2 1/4885XIAP 6/4885BIRC3 2/4885 |
| US-20200345714-A1 | Immunomodulation by IAP Inhibitors | BIRC2, BIRC3, BIRC5 | BIRC2 1/4885XIAP 6/4885BIRC3 2/4885 |
| US-20050234042-A1 | Organic compounds | AIFM1, BAX, API5 | BIRC2 9/4885XIAP 5/4885BIRC3 7/4885 |
| US-20110135691-A1 | IMMUNOMODULATION BY IAP INHIBITORS | BIRC2, BIRC3, BIRC5 | BIRC2 1/4885XIAP 6/4885BIRC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.